growth%20hormone%20deficiency%20(pediatric)
GROWTH HORMONE DEFICIENCY (PEDIATRIC)
Growth hormone deficiency is a congenital or an acquired growth hormone axis disruption in the higher brain, hypothalamus or pituitary which results in short stature.
It may occur at any age.
Short stature is often the only feature present in patients with growth hormone deficiency and other causes of subnormal growth rate.
Etiology may be congenital conditions (eg defective pituitary development that leads to pituitary aplasia, empty sella, encephalocele, midline defects) or acquired conditions (eg tumors of the hypothalamic-pituitary region, cranial irradiation, infiltrative disease).

Growth%20hormone%20deficiency%20(pediatric) Treatment

Principles of Therapy

Growth Hormone (GH) Replacement Therapy

  • GH replacement therapy is best accomplished under the direct supervision of a pediatric endocrinologist
  • Goals of pharmacotherapy
    • To restore normal GH levels and to reduce morbidity
    • To enable short children to achieve normal height with early improvement of the psychosocial problems related to short stature

Pharmacotherapy

Somatropin, Growth Hormone (GH), or Recombinant Human Growth Hormone (rhGH)

  • Synthetic polypeptide human GH of recombinant DNA (rDNA) origin
  • Indicated for children with growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, Noonan syndrome, short children small for gestational age, children with short stature homeobox-containing gene (SHOX) deficiency, and children with impaired growth due to chronic kidney disease
  • May also be used for children with idiopathic short stature (ISS) shorter than -2.25 SD score whose epiphyses are not closed, and with expected adult height below the normal range [160 cm (<63 in) for males, 150 cm (<59 in) for females]
  • Treatment should be started as soon as diagnosis of GHD is confirmed
  • GH trial therapy also recommended for children with otherwise unexplained short stature who pass GH stimulation tests, but who meet most of the following criteria:
    • Height >2.25 SD below the mean for age or >1.5 SD below the midparental height percentile
    • Growth velocity <25th percentile for bone age
    • Bone age >2 SD below the mean for age
    • Low serum IGF-1 and IGFBP-3
    • Other clinical features suggestive of GHD
  • Effects: Induce normal statural growth and correction of hypoglycemia
  • Target for treatment:
    • Satisfactory response is defined as an increase of height velocity of at least 2-2.5 cm/year above pre-treatment velocity
    • Achieve normal adult height
    • Attainment of bone age of 14 years (girls) and 16 years (boys)
  • Treatment should be started as soon as diagnosis of GHD is confirmed
  • Weight-based or body surface area (BSA)-based dosing is recommended  
  • Further studies are needed to prove the relationship between GH therapy during childhood and increased incidence of stroke in adolescents; preventive measures against stroke is advised for those with known risk factors

Gonadotropin-Releasing Hormone (GnRH) Agonist

  • Studies found GnRH agonist to be effective when given concurrently with recombinant GH
  • May delay epiphyseal fusion and prolong growth during puberty
  • Increases height and velocity in some GHD pediatric patients

Recombinant IGF-1/Mecasermin

  • Alternative treatment for patients with GH receptor abnormalities, STAT5b gene defects, and those with severe GHD unresponsive to therapy due to development of antibodies against GH
  • Further studies are needed to prove its efficacy in GHD
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
3 days ago
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.